HC Wainwright Reiterates Buy Rating on NMRA
HC Wainwright maintains its buy rating on NMRA with a $7 target, a 665.86% upside from the current price.
Key Points
- On June 16, 2026, HC Wainwright reiterated its buy rating on NMRA, setting a price target of $7.
- HC Wainwright's $7 price target implies 665.86% upside from Neumora Therapeutics, Inc.'s ($NMRA) current $0.91 share price.
- NMRA shares are trading around $0.91, reflecting a diverse range of institutional activities and insider transactions.
- Recent insider buying involved multiple executives acquiring 80,000 shares each, while institutional investors showed mixed activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, HC Wainwright reiterated its buy rating on NMRA, maintaining a price target of $7. This decision comes as NMRA shares trade near $0.91, suggesting potential upside according to the firm's analysis.
Other Institutional Activity in NMRA
SIREN, L.L.C. increased its holdings in NMRA by 2,209,039 shares, ending with 8,497,822 shares valued at approximately $16.57 million. In contrast, SoftBank Group Corp. trimmed its position by 339,419 shares, holding 6,090,301 shares worth about $11.88 million. Perceptive Advisors LLC took a new position with 5,104,097 shares valued at $9.95 million, while MIC Capital Management UK LLP kept its stake unchanged at 4,460,700 shares, valued at $8.70 million. Vanguard Capital Management LLC also initiated a new position, acquiring 3,891,893 shares valued at $7.59 million.
Neumora Therapeutics, Inc. Stock Down 34.2%
Shares of NMRA are currently trading around $0.91. The stock's recent institutional activities and analyst ratings reflect varying perspectives on its potential value. The company's market performance will be closely watched by investors, especially in light of these new recommendations and position changes.
Insider Buying and Selling at Neumora Therapeutics, Inc.
On May 27, 2026, several insiders, including Matthew Fust, Maykin Ho, Kristina Burow, Alaa Halawa, and David Piacquad, each purchased 80,000 shares of NMRA. These transactions were not part of a prearranged trading plan. Earlier in the year, on February 17, 2026, Michael Lee Milligan, NMRA's Chief Financial Officer and Principal Accounting Officer, sold 1,436 shares at an average price of $3.56.
Analysts Set New Price Targets
On June 16, 2026, HC Wainwright & Co. maintained its buy rating for NMRA with a $7 price target. Previously, on March 31, 2026, Guggenheim and Needham both reiterated their buy ratings, setting targets at $14 and $8, respectively. RBC Capital had upgraded NMRA to a buy rating with a $7 target on December 1, 2025. The consensus among analysts is a buy rating, with a mean target price reflecting optimism about NMRA's future prospects.
Bottom Line
HC Wainwright's reiterated buy rating and $7 target for NMRA highlight the firm's confidence in the stock's potential. Investors track these ratings and insider transactions to gauge market sentiment and potential future performance. As always with 13F filings and analyst ratings, these insights are based on past data and projections, and actual market conditions may vary.
Get Neumora Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NMRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.